MBRX Latest Headlines

Roth MKM Remains a Buy on Moleculin Biotech (MBRX)

at www.tipranks.com (Mon, 23-Feb 8:45 AM)

Moleculin Raises $6.5 Million from Warrant Exercises—Fresh Capital and New Warrants Set the Stage for 2026

Market Chameleon (Wed, 10-Dec 9:02 AM)

Moleculin’s New Annamycin Brain Tumor Collaboration Targets Unmet Needs in Glioblastoma

Market Chameleon (Mon, 8-Dec 8:48 AM)